Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is featured in a BioMedWire editorial examining the need for new approaches to treating multiple sclerosis (MS), a progressive neurological disease affecting more than 2.9 million people worldwide. The editorial, titled "The Quest to Repair What Multiple Sclerosis Takes Away", highlights the limitations of current therapies, which can slow disease progression but cannot stop it completely.
The editorial discusses Quantum BioPharma's development of Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath damaged by MS. The company said the potential therapy is preparing to advance into Phase 2 clinical trials as it pursues a novel approach to treating the disease. Unlike existing treatments that focus on modulating the immune system to reduce attacks on myelin, Lucid-MS aims to prevent and reverse myelin degradation, addressing the underlying mechanism of MS.
This development is significant because MS remains an incurable condition with a high unmet medical need. Current disease-modifying therapies can reduce relapse rates and delay progression, but they do not restore lost function. A drug that can repair myelin could potentially reverse disability, offering hope to millions of patients. Quantum BioPharma's focus on remyelination represents a paradigm shift in MS research.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., it is advancing Lucid-MS. The company also has interests in other ventures, including a stake in Unbuzzd Wellness Inc., which markets an over-the-counter product for alcohol metabolism.
The editorial underscores the importance of continued investment in novel approaches to MS. For investors, Quantum BioPharma's progress in clinical trials could represent a significant opportunity. More information about the company is available in its newsroom at https://ibn.fm/QNTM.
